In this article, we explore the crucial role of shared decision-making in HIV treatment and…
Researchers from Gladstone Institutes and their partners at Xyphos Biosciences have demonstrated that a cell-based therapy, convertibleCAR®, appears to reduce the latent HIV reservoir in individuals on antiretroviral therapy.
Research presented at IDWeek has discovered that users of the social networking app, Grindr, took more risks and had more partners but were more likely to use, or be open to using, PrEP compared with those who didn’t use the app.
Researchers have developed an animal model mimicking HIV infection in infants, potentially allowing the development of therapeutics and interventions for the pediatric population.
In a new sequencing study, researchers discovered a transcriptional signature in B cells associated with protection from SIV or HIV infection.
US FDA approves RECARBRIO™ for complicated UTIs and complicated intra-abdominal infections: July’s industry headlines
Take a look at this month’s industry headlines including a US FDA approval for RECARBRIO™, positive results for XOFLUZA in children and new ACIP recommendations.
Find out more about the headlines from the 10th International AIDS Society Conference on HIV Science (IAS 2019) in our round-up of conference news.
Despite long-term antiretroviral therapy, cerebrospinal HIV reservoirs have been identified in individuals living with the virus and linked with a higher rate of cognitive defects.
A new study using CRISPR-Cas9 and long-acting slow-effective release antiretroviral therapy has reported the elimination of replication-competent HIV-1 DNA from the genomes of living animals for the first time.
In this interview we talk to Jose Arribas about the challenges facing antiretroviral treatments and the future of long-acting formulations for HIV. What new drugs might we have for this disease in the coming years? Read our interview to find out more.